Publikationen 1999

Germing U, Fischer R, Bauser U, Schneider M, Aul C.
Pneumococcal septicemia in functional asplenia: first manifestation of systemic autoimmune disease?
Z Rheumatol. 1999 Feb;58(1):31-4.

Muschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Haussinger D.
Involvement of soluble CD95 in Churg-Strauss syndrome.
Am J Pathol 1999; 155(3):915-25

Ostendorf B, Dann P, Wedekind F, Brauckmann U, Friemann J, Koebke J, Schulitz KP, Schneider M
Miniarthroscopy of metacarpophalangeal joints in rheumatoid arthritis. Rating of diagnostic value in synovitis staging and efficiency of synovial biopsy.
J Rheumatol. 1999 Sep;26(9):1901-8

Pascher E, Perniok A, Becker A, Feldkamp J.
Effect of 1alpha,25(OH)2-vitamin D3 on TNF alpha-mediated apoptosis of human primary osteoblast-like cells in vitro.
Horm Metab Res 1999; 31(12): 653-6.

Rademacher J, Sohngen D, Specker C, Janda I, Sitzer M.
Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?
Acta Neurol Scand. 1999 Jun;99(6):356-61.

Sander O, Herborn G, Bock E und Rau R.
Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate.
Ann Rheum Dis 1999; 281-7

Schneider M.
Response and remission criteria for clinical trials in lupus-what can we learn from other diseases?
Lupus 1999;8(8):627-31.

Seissler J, Schott M, Boms S, Wohlrab U, Ostendorf B, Morgenthaler NG, Scherbaum WA.
Autoantibodies to human tissue transgutaminase identify silent coeliac disease in Type I diabetes.
Diabetologia 1999 Dec;42(12):1440-1

Swaak AJ, van den Brink HG, Smeenk RJ, Manger K, Kalden JR, Tosi S, Marchesoni A, Domljan Z, Rozman B, Logar D, Pokorny G, Kovacs L, Kovacs A, Vlachoyiannopoulos PG, Moutsopoulos HM, Chwalinska-Sadowska H, Dratwianka B, Kiss E, Cikes N, Branimir A, Schneider M, Fischer R, Bombardieri S, Mosca M, Smolen JS.
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation.
Rheumatology (Oxford). 1999 Oct;38(10):953-8.

von Schmiedeberg S, Fritsche E, Ronnau AC, Specker C, Golka K, Richter-Hintz D, Schuppe HC, Lehmann P, Ruzicka T, Esser C, Abel J, Gleichmann E.
Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus.
Adv Exp Med Biol. 1999;455:147-52.

PUBLIKATIONEN

MediathekInformation und Wissen
LageplanSo finden Sie uns